From 8d2827130f91fceb6f3c33b5f1dcd1a1d8f0e62b Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Sun, 15 Mar 2026 19:07:50 +0000 Subject: [PATCH] extract: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics Pentagon-Agent: Ganymede --- ...t cost impact inflationary through 2035.md | 6 ++++ ...-cardiovascular-and-metabolic-endpoints.md | 6 ++++ ...eating-largest-per-patient-cost-savings.md | 6 ++++ ...e conditions faster than prices decline.md | 6 ++++ ...ensive-semaglutide-medicare-economics.json | 32 +++++++++++++++++++ ...ehensive-semaglutide-medicare-economics.md | 20 +++++++++++- 6 files changed, 75 insertions(+), 1 deletion(-) create mode 100644 inbox/archive/.extraction-debug/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.json diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 1bdac78a3..4620c1fe7 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -23,6 +23,12 @@ The competitive dynamics (Lilly vs. Novo vs. generics post-2031) will drive pric Real-world persistence data from 125,474 commercially insured patients shows the chronic use model fails not because patients choose indefinite use, but because most cannot sustain it: only 32.3% of non-diabetic obesity patients remain on GLP-1s at one year, dropping to approximately 15% at two years. This creates a paradox for payer economics—the "inflationary chronic use" concern assumes sustained adherence, but the actual problem is insufficient persistence. Under capitation, payers pay for 12 months of therapy ($2,940 at $245/month) for patients who discontinue and regain weight, capturing net cost with no downstream savings from avoided complications. The economics only work if adherence is sustained AND the payer captures downstream benefits—with 85% discontinuing by two years, the downstream cardiovascular and metabolic savings that justify the cost never materialize for most patients. + +### Additional Evidence (challenge) +*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-15* + +Value in Health peer-reviewed modeling study (2025) found that comprehensive semaglutide access to Medicare beneficiaries produces net savings of $715M over 10 years (range $412M-$1.04B) when accounting for multi-indication benefits across T2D, obesity, and MASH. The study modeled 38,950 avoided CV events and 6,180 prevented deaths, with T2D-related savings of $892M exceeding obesity-related costs of $205M. This challenges the 'inflationary through 2035' framing by demonstrating that under risk-bearing payment structures where a single payer captures both costs and downstream savings, GLP-1s can be cost-neutral or cost-saving. The divergence between system-level inflation and payer-level savings suggests the 'inflationary' claim needs scope qualification—it may be true at the system level due to misaligned incentives, but false for integrated payers bearing full risk. + --- Relevant Notes: diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index 1222d36b5..b8904bdb8 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr - Nature Medicine: additive benefits with SGLT2 inhibitors - First GLP-1 to receive FDA indication for CKD in T2D patients + +### Additional Evidence (extend) +*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-15* + +Medicare modeling study quantifies the compounding value: per-subject savings of $14,431 from avoided T2D complications, $2,074 from avoided CKD progression, and $1,512 from avoided CV events, totaling $18,017 in downstream savings against $47,353 in lifetime drug costs. Over 10 years across the Medicare population, this translates to 38,950 CV events avoided, 6,180 deaths prevented, with specific breakdowns of 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, and 487 non-fatal strokes avoided per 100,000 subjects treated. The T2D savings ($892M) substantially exceed obesity costs ($205M) at the population level, demonstrating that multi-organ protection creates measurable economic value when a single payer captures all benefits. + --- Relevant Notes: diff --git a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md index 5299ec097..a1f6a1c41 100644 --- a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md +++ b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md @@ -28,6 +28,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, - FDA indication expansion to T2D patients with CKD (2024) - Dialysis cost benchmark: $90K+/year per patient + +### Additional Evidence (extend) +*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-15* + +Medicare modeling study quantifies CKD-related savings at $2,074 per subject from avoided kidney disease progression and delayed dialysis. At the population level, CKD benefits contribute to the overall $715M net savings over 10 years, though the per-patient CKD savings are smaller than T2D savings ($14,431) or CV savings ($1,512). The study confirms that kidney protection is a meaningful but not dominant component of semaglutide's economic value proposition in the Medicare population. + --- Relevant Notes: diff --git a/domains/health/the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md b/domains/health/the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md index a23f37e51..83176421c 100644 --- a/domains/health/the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md +++ b/domains/health/the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md @@ -37,6 +37,12 @@ The composition of spending shifts dramatically: less on chronic disease managem (extend) The Medicare trust fund fiscal pressure adds a constraint layer to the cost curve dynamics. While new capabilities create upward cost pressure through expanded treatment populations, the trust fund exhaustion timeline (now 2040, accelerated from 2055 by tax policy changes) creates a hard fiscal boundary. The convergence of demographic pressure (working-age to 65+ ratio declining to 2.2:1 by 2055), MA overpayments ($1.2T/decade), and reduced tax revenues means automatic 8-10% benefit cuts starting 2040 unless structural reforms occur. This fiscal ceiling will force coverage and payment decisions in the 2030s independent of technology trajectories, potentially constraining the cost curve expansion that new capabilities would otherwise enable. + +### Additional Evidence (extend) +*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-15* + +The Medicare semaglutide study provides a concrete example of the cost curve dynamic: even when a prevention intervention (semaglutide) produces net savings for a risk-bearing payer ($715M over 10 years), the system-level impact may still be inflationary because the drug creates new treatment-eligible populations faster than it reduces downstream costs. The study's finding that obesity-related costs add $205M while T2D and MASH savings total $920M demonstrates that prevention can be cost-saving within a closed system, but the expansion of treatment-eligible populations (from T2D-only to obesity to MASH) increases total spending even as per-patient value improves. This is the healthcare cost curve in microcosm: better capabilities create more treatable conditions. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.json b/inbox/archive/.extraction-debug/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.json new file mode 100644 index 000000000..f634dd553 --- /dev/null +++ b/inbox/archive/.extraction-debug/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.json @@ -0,0 +1,32 @@ +{ + "rejected_claims": [ + { + "filename": "comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-cardiovascular-and-metabolic-benefits-offset-drug-costs-when-single-payer-bears-both-costs-and-savings.md", + "issues": [ + "missing_attribution_extractor" + ] + }, + { + "filename": "glp-1-cost-effectiveness-depends-on-payment-structure-because-capitated-payers-capture-downstream-savings-while-fee-for-service-systems-separate-drug-costs-from-complication-savings.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-cardiovascular-and-metabolic-benefits-offset-drug-costs-when-single-payer-bears-both-costs-and-savings.md:set_created:2026-03-15", + "glp-1-cost-effectiveness-depends-on-payment-structure-because-capitated-payers-capture-downstream-savings-while-fee-for-service-systems-separate-drug-costs-from-complication-savings.md:set_created:2026-03-15" + ], + "rejections": [ + "comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-cardiovascular-and-metabolic-benefits-offset-drug-costs-when-single-payer-bears-both-costs-and-savings.md:missing_attribution_extractor", + "glp-1-cost-effectiveness-depends-on-payment-structure-because-capitated-payers-capture-downstream-savings-while-fee-for-service-systems-separate-drug-costs-from-complication-savings.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-15" +} \ No newline at end of file diff --git a/inbox/archive/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md b/inbox/archive/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md index e5b44f11a..c6db7d0c1 100644 --- a/inbox/archive/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md +++ b/inbox/archive/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md @@ -7,9 +7,13 @@ date: 2025-06-01 domain: health secondary_domains: [internet-finance] format: paper -status: unprocessed +status: enrichment priority: high tags: [glp-1, semaglutide, medicare, cost-effectiveness, cardiovascular, CKD, MASH] +processed_by: vida +processed_date: 2026-03-15 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -39,3 +43,17 @@ Key findings: PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: This study provides the strongest evidence that the "inflationary through 2035" framing needs scope qualification — system-level vs. payer-level economics diverge when downstream savings accrue to the same entity EXTRACTION HINT: Focus on the distinction between system-level cost impact (inflationary) and risk-bearing payer impact (potentially cost-saving). This is the core VBC interaction. + + +## Key Facts +- Medicare semaglutide modeling study estimated net savings of $715 million over 10 years (2026-2035) with range of $412M to $1.04B +- Study modeled 38,950 cardiovascular events avoided over 10 years +- Study estimated 6,180 deaths avoided (CV events + CKD/MASH progression) +- T2D-related impact: savings of ~$892 million +- Obesity-related impact: added costs of ~$205 million +- MASH-related impact: savings of ~$28 million +- Per 100,000 subjects treated: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided, 115 CV deaths avoided +- Average per-subject lifetime treatment costs: $47,353 +- Savings from avoided T2D: $14,431/subject; avoided CKD: $2,074/subject; avoided CV events: $1,512/subject +- Study published in Value in Health, peer-reviewed health economics journal +- Study used Novo Nordisk-favorable assumptions including net prices with rebates